{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:31:40Z","timestamp":1791189100699,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.neulet.2009.05.035","type":"journal-article","created":{"date-parts":[[2009,5,19]],"date-time":"2009-05-19T05:29:45Z","timestamp":1242710985000},"page":"82-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation"],"prefix":"10.1016","volume":"460","author":[{"given":"Adeline","family":"Etievant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"B\u00e9try","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Arnt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Haddjeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2009.05.035_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eurpsy.2004.11.003","article-title":"Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies","volume":"20","author":"Abi-Dargham","year":"2005","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.neulet.2009.05.035_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neubiorev.2004.05.001","article-title":"The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems","volume":"28","author":"Adell","year":"2004","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neulet.2009.05.035_bib3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00213-007-0698-y","article-title":"In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain","volume":"191","author":"Bortolozzi","year":"2007","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neulet.2009.05.035_bib4","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/S0924-977X(07)70689-2","article-title":"P.3.c.052 long-term efficacy and safety of bifeprunox in stable patients with schizophrenia: findings from a 6-month study","volume":"17","author":"Bourin","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neulet.2009.05.035_bib5","first-page":"577","article-title":"d-Amphetamine-induced inhibition of central dopaminergic neurons: direct effect or mediated by a striatonigral feedback pathway?","volume":"16","author":"Bunney","year":"1977","journal-title":"Adv. Biochem. Psychopharmacol."},{"key":"10.1016\/j.neulet.2009.05.035_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-008-1207-7","article-title":"Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study","volume":"200","author":"Casey","year":"2008","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neulet.2009.05.035_bib7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0028-3908(03)00113-8","article-title":"Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors","volume":"44","author":"Chaperon","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neulet.2009.05.035_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0014-2999(00)00149-7","article-title":"The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors","volume":"394","author":"Cussac","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2009.05.035_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/0269881108089586","article-title":"Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour","volume":"23","author":"Dahan","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neulet.2009.05.035_bib10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nn1103","article-title":"Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission","volume":"6","author":"Floresco","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neulet.2009.05.035_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0306-4522(88)90307-7","article-title":"Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry","volume":"24","author":"Gonon","year":"1988","journal-title":"Neuroscience"},{"key":"10.1016\/j.neulet.2009.05.035_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0306-4522(83)90135-5","article-title":"Intracellular and extracellular electrophysiology of nigral dopaminergic neurons\u20141. Identification and characterization","volume":"10","author":"Grace","year":"1983","journal-title":"Neuroscience"},{"key":"10.1016\/j.neulet.2009.05.035_bib13","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1523\/JNEUROSCI.18-06-02231.1998","article-title":"Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice","volume":"18","author":"Koeltzow","year":"1998","journal-title":"J. Neurosci."},{"issue":"Suppl. A","key":"10.1016\/j.neulet.2009.05.035_bib14","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.clinthera.2005.07.017","article-title":"Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation","volume":"27","author":"Laruelle","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.neulet.2009.05.035_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0031-6997(24)01327-9","article-title":"The D3 dopamine receptor: neurobiology and potential clinical relevance","volume":"49","author":"Levant","year":"1997","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neulet.2009.05.035_bib16","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1016\/S0924-977X(05)81010-7","article-title":"P.3.074 bifeprunox: a novel atypical antipsychotic sharing dopamine D(2,3,4) receptor and serotonin 5-HT(1A) receptor affinities","volume":"15","author":"Marquis","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neulet.2009.05.035_bib17","first-page":"323","article-title":"Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice","volume":"79","author":"Mercuri","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.neulet.2009.05.035_bib18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0022-3565(24)39333-4","article-title":"S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626","volume":"293","author":"Millan","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2009.05.035_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1124\/jpet.107.126706","volume":"324","author":"Millan","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2009.05.035_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0006-3223(99)00078-5","article-title":"The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia","volume":"46","author":"Moore","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2009.05.035_bib21","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.pnpbp.2004.06.020","article-title":"Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism","volume":"28","author":"Naber","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neulet.2009.05.035_bib22","first-page":"539","article-title":"Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics","volume":"8","author":"Newman-Tancredi","year":"2007","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.neulet.2009.05.035_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/026988110401800303","article-title":"Receptor mechanisms in the treatment of schizophrenia","volume":"18","author":"Reynolds","year":"2004","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neulet.2009.05.035_bib24","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neulet.2009.05.035_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2008.09.008","article-title":"Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors","volume":"597","author":"Tadori","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2009.05.035_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2007.07.031","article-title":"Differences in agonist\/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912","volume":"574","author":"Tadori","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2009.05.035_bib27","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1126\/science.1093360","article-title":"Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli","volume":"303","author":"Ungless","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.neulet.2009.05.035_bib28","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1126\/science.6136093","article-title":"Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons","volume":"221","author":"White","year":"1983","journal-title":"Science"}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394009006594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394009006594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:09:29Z","timestamp":1759608569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394009006594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0304394009006594"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2009.05.035","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2009.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}